Early research (Phase 1)Study completedNCT03941262
What this trial is testing
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
Who this might be right for
Refractory CancerMetastatic CancerRecurrent Cancer+4 more
NKGen Biotech, Inc. 27